Lionco Pharmaceutical Group Co.,Ltd.

SHSE:603669 Voorraadrapport

Marktkapitalisatie: CN¥3.4b

De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Lionco Pharmaceutical GroupLtd Beheer

Beheer criteriumcontroles 2/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Ling Ping Tao

Algemeen directeur

CN¥660.0k

Totale compensatie

Percentage CEO-salarisn/a
Dienstverband CEOno data
Eigendom CEO6.8%
Management gemiddelde ambtstermijngeen gegevens
Gemiddelde ambtstermijn bestuurgeen gegevens

Recente managementupdates

Recent updates

Lionco Pharmaceutical Group Co.,Ltd. (SHSE:603669) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected

May 10
Lionco Pharmaceutical Group Co.,Ltd. (SHSE:603669) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected

There's Reason For Concern Over Lionco Pharmaceutical Group Co.,Ltd.'s (SHSE:603669) Massive 28% Price Jump

Mar 12
There's Reason For Concern Over Lionco Pharmaceutical Group Co.,Ltd.'s (SHSE:603669) Massive 28% Price Jump

CEO

Ling Ping Tao (54 yo)

no data

Tenure

CN¥660,000

Compensatie

Ms. Ling Ping Tao is General Manager of Lionco Pharmaceutical Group Co.,Ltd. and serves as its Chairman of the Board.